Molecular diagnosis refers to the technique of using molecular biological methods to detect changes in the structure or expression level of genetic material in patients to make a diagnosis.

To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab’s ability to dynamically respond to today’s rapidly changing testing environment. The solution can be used by a variety of labs performing routine quantitative polymerase chain reaction (qPCR) diagnostic tests and by developers to increase the speed of innovation for emerging testing solutions.

Fortis Life Sciences on Wednesday said it has acquired diagnostic testing component maker International Point of Care.

Alveo Technologies said on Tuesday that it has partnered with Germany's Fraunhofer Institute for Cell Therapy and Immunology IZI to develop molecular diagnostic tests for the veterinary space.

Helio Genomics said Thursday that its sister company, Laboratory for Advanced Medicine & Health Group (LAMH), has received approval from the National Medical Products Administration (NMPA) in China for its cell-free DNA-based liver cancer detection test. The assay is the first of its kind to receive this approval.

The US Food and Drug Administration announced on Tuesday that it has launched a voluntary pilot program intended to reduce the risks of laboratory-developed tests used to select patients for oncology therapies.

Breast Cancer Canada said on Thursday that it has launched a new grant program in collaboration with AstraZeneca Canada and Illumina.

Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem™ Business.

Point-of-care testing (POCT), also known as "bedside testing" or "near-patient testing," is a test performed near or at the patient's location that may result in a change in the patient's disposition.

The US Food and Drug Administration in May granted 510(k) clearances for tests and testing systems by Abbott, Hologic, and Becton Dickinson, among others.